- Home
- LQDA
LQDA
Liquidia Corporation
as 07-26-2024 4:00pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 938.0M | IPO Year: | 2018 |
| Target Price: | $26.25 | AVG Volume (30 days): | 902.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.71 - $16.99 | Next Earning Date: | 08-08-2024 |
| Revenue: | $15,967,000 | Revenue Growth: | -5.72% |
| Revenue Growth (this year): | 296.46% | Revenue Growth (next year): | 208.29% |
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kaseta Michael | LQDA | CFO and COO | Jul 12 '24 | Sell | $12.53 | 3,906 | $48,942.18 | 312,389 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Jul 12 '24 | Sell | $12.53 | 1,470 | $18,419.10 | 210,202 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | Jul 12 '24 | Sell | $12.53 | 1,985 | $24,872.05 | 485,676 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Jul 11 '24 | Sell | $12.53 | 1,146 | $14,359.38 | 115,226 | SEC Form 4 |
| Moomaw Scott | LQDA | Chief Commercial Officer | May 31 '24 | Sell | $14.55 | 546 | $7,944.30 | 153,210 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | May 31 '24 | Sell | $14.55 | 710 | $10,330.50 | 487,661 | SEC Form 4 |
| Kaseta Michael | LQDA | CFO and COO | May 31 '24 | Sell | $14.55 | 1,094 | $15,917.70 | 316,295 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | May 31 '24 | Sell | $14.55 | 455 | $6,620.25 | 112,465 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Apr 19 '24 | Sell | $13.68 | 1,649 | $22,558.32 | 211,672 | SEC Form 4 |
| JEFFS ROGER | LQDA | Chief Executive Officer | Apr 12 '24 | Sell | $14.58 | 8,360 | $121,888.80 | 826,985 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | Apr 12 '24 | Sell | $14.58 | 2,060 | $30,034.80 | 486,027 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Apr 12 '24 | Sell | $14.58 | 1,525 | $22,234.50 | 213,321 | SEC Form 4 |
| Moomaw Scott | LQDA | Chief Commercial Officer | Apr 12 '24 | Sell | $14.58 | 1,585 | $23,109.30 | 151,881 | SEC Form 4 |
| Kaseta Michael | LQDA | CFO and COO | Apr 12 '24 | Sell | $14.58 | 3,136 | $45,722.88 | 315,045 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Apr 11 '24 | Sell | $14.58 | 1,189 | $17,335.62 | 111,537 | SEC Form 4 |
| Kaseta Michael | LQDA | CFO and COO | Mar 19 '24 | Sell | $15.82 | 851 | $13,462.82 | 329,496 | SEC Form 4 |
| Kaseta Michael | LQDA | CFO and COO | Mar 19 '24 | Sell | $15.82 | 11,315 | $179,003.30 | 318,181 | SEC Form 4 |
| JEFFS ROGER | LQDA | Chief Executive Officer | Mar 18 '24 | Sell | $15.82 | 28,583 | $452,183.06 | 835,345 | SEC Form 4 |
| Moomaw Scott | LQDA | Chief Commercial Officer | Mar 18 '24 | Sell | $15.82 | 6,108 | $96,628.56 | 153,466 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Mar 18 '24 | Sell | $15.82 | 1,654 | $26,166.28 | 220,722 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Mar 18 '24 | Sell | $15.82 | 5,876 | $92,958.32 | 214,846 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Mar 15 '24 | Sell | $15.82 | 4,581 | $72,471.42 | 108,716 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Mar 15 '24 | Sell | $15.50 | 76 | $1,178.00 | 108,640 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | Mar 15 '24 | Sell | $15.82 | 715 | $11,311.30 | 496,025 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | Mar 15 '24 | Sell | $15.82 | 7,938 | $125,579.16 | 488,087 | SEC Form 4 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
High Insider Ownership Marks These US Growth Companies For July 2024
MT Newswires
a month ago
Oppenheimer Initiates Liquidia at Perform
Simply Wall St.
a month ago
High Insider Ownership Growth Companies On US Exchange For June 2024
GlobeNewswire
a month ago
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
Simply Wall St.
2 months ago
Liquidia Insiders Placed Bullish Bets Worth US$3.00m
Investor's Business Daily
2 months ago
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
MT Newswires
2 months ago
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction
GlobeNewswire
2 months ago
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
Compare LQDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.